Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts signal growth. Click for my CRSP update.

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...

In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized ...

The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...